Pfizer Inc said on Friday that its experimental rheumatoid arthritis drug met the main goals of a late-stage clinical trial, a welcome boost for the world's largest drugmaker as it seeks new products to offset those that are losing patent protection.
Pfizer arthritis drug meets main goals of trial